Advertisement

Managing Pediatric Patients with Psoriasis

  • Susan Bard
  • Daniele Torchia
  • Lawrence A. Schachner
Review Article

Abstract

Childhood-onset psoriasis affects approximately one-third of the psoriatic population. Among many potential treatments of childhood psoriasis, biological agents are emerging as a valuable option in the management of this disease. InEurope, etanercept has recently been approved for children aged 8 years and over. Data froma well-designed clinical trial indicate that in children, etanercept effectively reduces psoriasis symptoms, with beneficial effects evident as early as 4 weeks after the initiation of treatment. Etanercept iswell tolerated; adverse effects are typically mild to moderate in severity. Early data from other biological agents are promising.

Keywords

Psoriasis Infliximab Etanercept Juvenile Rheumatoid Arthritis Plaque Psoriasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Editorial assistance for the preparation of this manuscript was provided by Stephanie Blick of inScience Communications. This assistance was funded by Pfizer. The authors report no conflicts of interest.

References

  1. 1.
    Sukhatme SV, Gottlieb AB. Pediatric psoriasis: updates in biologic therapies. Dermatol Ther 2009; 22: 34–9PubMedCrossRefGoogle Scholar
  2. 2.
    Marcoux D, Prost Y. Pediatric psoriasis revisited. J Cutan Med Surg 2002; 6 (3 Suppl.): 22–8PubMedCrossRefGoogle Scholar
  3. 3.
    Duffin KC, Krueger GG. Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association. J Invest Dermatol 2009; 129: 827–33PubMedCrossRefGoogle Scholar
  4. 4.
    Cordoro KM. Management of childhood psoriasis. Adv Dermatol 2008; 24: 125–69PubMedCrossRefGoogle Scholar
  5. 5.
    EPARs for authorised medicinal products for human use. Enbrel. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/enbrel/enbrelM2.htm
  6. 6.
    Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Demiatol 2003; 49: 171–82CrossRefGoogle Scholar
  7. 7.
    Pasic A, Ceovic R, Lipozencic J, et al. Phototherapy in pediatric patients. Pediatr Dermatol 2003; 20: 71–7PubMedCrossRefGoogle Scholar
  8. 8.
    Herbst RA, Hoch O, Kapp A, et al. Guttate psoriasis triggered by perianal streptococcal dermatitis in a four-year-old boy. J Am Acad Dermatol 2000; 42: 885–7PubMedCrossRefGoogle Scholar
  9. 9.
    Hawrot AC, Metry DW, Theos AJ, et al. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol 2006; 23: 67–71PubMedCrossRefGoogle Scholar
  10. 10.
    Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358: 241–51PubMedCrossRefGoogle Scholar
  11. 11.
    Pereira TM, Vieira AP, Fernandes JC, et al. Anti-TNF-alpha therapy in childhood pustular psoriasis. Dermatology 2006; 213: 350–2PubMedCrossRefGoogle Scholar
  12. 12.
    FDA: CancerWarnings Required for TNF Blockers. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Susan Bard
    • 1
  • Daniele Torchia
    • 1
  • Lawrence A. Schachner
    • 1
  1. 1.Department of Dermatology and Cutaneous SurgeryUniversity of Miami Miller School of MedicineMiamiUSA

Personalised recommendations